Navigation Links
Aytu BioScience to Present at Two Upcoming Investor Conferences

ENGLEWOOD, Colo., Nov. 30, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage specialty healthcare company focused on urological and related conditions, will present at two upcoming investor conferences. Aytu is scheduled to present live at, an interactive real-time virtual conference, to be held December 3, 2015, and at LD Micro's Main Event Investor Conference, to be held December 2nd & 3rd, 2015 in Los Angeles and streamed live via webcast.

Josh Disbrow, Chief Executive Officer, will provide an overview of the Company's business during his live presentations and will be available to participate in one-on-one meetings with investors who are registered to attend LD Micro's Main Event Investor Forum.Event:LD Micro's Main Event Investor ConferenceDate: Wednesday, December 2, 2015Time: 8:30 am (Pacific Time) Location:Luxe Sunset Bel Air, Los Angeles, CA Link: Date: Thursday, December 3, 2015 Time: 11:30 am (Eastern Time) Link:

The presentation will be webcast live and remain available for an additional 90 days following the live presentation. To access the webcast, please visit the Investors section of the Aytu website at

About Aytu BioScience, Inc.

Aytu BioScience, Inc. is a commercial-stage specialty healthcare company focused on urological and related conditions. The Company's products includes FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody that targets Prostate Specific Membrane Antigen (PSMA), a protein highly expressed by prostate cancer; as well as Primsol® (trimethoprim oral solution), the only FDA-approved oral solution of trimethoprim, the standard therapy for urinary tract infections.  Aytu's strategy is to continue building its portfolio of revenue-generating urology products and late-stage development assets, leveraging its commercial team and expertise to further build those brands within well-established markets.

Forward Looking Statement

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation, statements regarding the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaborations. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without limitation to the risks described in "Risk Factors" in Part I, Item 1A of Aytu BioScience, Inc. Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time. These risks are not exhaustive. Other sections of Aytu BioScience, Inc. Annual Report on Form 10-K and such other filed reports and documents include additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We assume no obligation to update or supplement forward-looking statements.

Logo - 


SOURCE Aytu BioScience, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
2. The BioVoyage Institute is seeking the help of corporations, organizations, institutions, communities and individuals to help with bioscience and biotechnology education
3. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
4. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
5. Northstar Biosciences Launches All Natural Skincare Solutions
6. Blanchette Rockefeller Neurosciences Institute Partners with Neurotrope BioScience to Advance New Alzheimers Disease Discoveries
7. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
8. Seahorse Bioscience Announces AACR Travel Award Recipients
9. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
10. Jennifer C. Smith, DVM DACLAM, Formerly of Taconic Farms, Inc. Joins the Veterinary Bioscience Institute as the Vice President of Research and Development
11. Nanotechnologies in Bioscience, Live Webinar on May 10
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and recently ... have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. ... for gene editing across all applications. , Under the terms of the agreement, ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded ... of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for ... fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalind™, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
Breaking Biology Technology:
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
Breaking Biology News(10 mins):